Search
Search Constraints
You searched for: Author/Creator Kupper, HLimit your search
- Kupper, H [remove] 11
- 616.723005 11
- Rheumatism -- Periodicals 11
- ACR, American College of Rheumatology -- AEs, adverse events -- ANAs, antinuclear antibodies -- ANCOVA, analysis of covariance -- CRP, C reactive protein -- CTC, Common Toxicity Criteria -- DAS, disease activity score -- DMARDs, disease modifying antirheumatic drugs -- dsDNA, double stranded DNA -- ESR, erythrocyte sedimentation rate -- HAQ, Health Assessment Questionnaire -- ITT, intention to treat -- MTX, methotrexate -- NSAIDs, non-steroidal anti-inflammatory drugs -- RA, rheumatoid arthritis -- sc, subcutaneously -- SJC, swollen joint count -- TJC, tender joint count -- TNFα, tumour necrosis factor α 1
- ACR, American College of Rheumatology -- ANA, antinuclear antibody -- CRP, C reactive protein -- DAS, disease activity score -- DMARDs, disease modifying antirheumatic drugs -- ESR, erythrocyte sedimentation rate -- EULAR, European League Against Rheumatism -- HAQ DI, Disability Index of the Health Assessment Questionnaire -- MTX, methotrexate -- NSAIDs, non-steroidal anti-inflammatory drugs -- RA, rheumatoid arthritis -- TNF, tumour necrosis factor 1
- AE, adverse event -- CDC, Centers for Disease Control -- CHF, congestive heart failure -- DMARD, disease modifying antirheumatic drug -- E/100 PYs, events per 100 patient-years -- FDA, Food and Drug Administration -- LTB, latent TB -- MTX, methotrexate -- OLE, open label extension trial -- PY, patient-year -- RA, rheumatoid arthritis -- RCT, randomised controlled trial -- SAE, serious adverse event -- SEER, Surveillance, Epidemiology and End Results -- SIR, standardised incidence ratio -- SLE, systemic lupus erythematosus -- TB, tuberculosis -- TNF, tumour necrosis factor -- TST, tuberculin skin test 1
- adalimumab -- disease modifying antirheumatic drugs -- human monoclonal antibodies -- monotherapy -- rheumatoid arthritis -- tumour necrosis factor α 1
- adalimumab -- monoclonal antibodies -- tumour necrosis factor α -- rheumatoid arthritis -- disease modifying antirheumatic drugs 1
- adalimumab -- postmarketing surveillance -- rheumatoid arthritis -- safety -- tumour necrosis factor antagonists 1